CN Patent

CN108125923A — 用于治疗骨髓纤维化的组合物和方法

Assigned to Biomedical Impact Co · Expires 2018-06-08 · 8y expired

What this patent protects

本申请涉及用于治疗骨髓纤维化的组合物和方法。本申请提供的是用于治疗受试者的骨髓纤维化的组合物和方法。所述方法包括向所述受试者给药有效量的化合物，所述化合物为N‑叔丁基‑3‑[(5‑甲基‑2‑{[4‑(2‑吡咯烷‑1‑基乙氧基)苯基]氨基}嘧啶‑4‑基)氨基]苯磺酰胺或其药用盐或其水合物。

USPTO Abstract

本申请涉及用于治疗骨髓纤维化的组合物和方法。本申请提供的是用于治疗受试者的骨髓纤维化的组合物和方法。所述方法包括向所述受试者给药有效量的化合物，所述化合物为N‑叔丁基‑3‑[(5‑甲基‑2‑{[4‑(2‑吡咯烷‑1‑基乙氧基)苯基]氨基}嘧啶‑4‑基)氨基]苯磺酰胺或其药用盐或其水合物。

Drugs covered by this patent

Patent Metadata

Patent number
CN108125923A
Jurisdiction
CN
Classification
—
Expires
2018-06-08
Drug substance claim
No
Drug product claim
No
Assignee
Biomedical Impact Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.